Dupilumab restores skin barrier function in children with moderate-to-severe atopic dermatitis, study shows

A new study led by investigators at National Jewish Health and published in Annals of Allergy, Asthma & Immunology shows that treatment with dupilumab significantly restores skin barrier function and reduces inflammation in children ages 6 to 11 with moderate-to-severe atopic dermatitis (eczema). Using advanced, noninvasive techniques, researchers found improvements not only in visible eczema lesions but also in clinically unaffected skin, highlighting the systemic nature of the disease.